Current evidence on the relationship between polymorphisms in the COX-2 gene and breast cancer risk: a meta-analysis

The association between single-nucleotide polymorphisms (SNPs) in the COX-2 gene and breast cancer risk is still ambiguous. We here try to derive a more precise estimation of the relationship by performing a meta-analysis based on currently available evidence from literature. More than 15 SNPs have been studied, and the most studied genetic variants were rs5275, rs5277, and rs20417. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association between each polymorphism and breast cancer risk under the codominant model, dominant model, and recessive model, respectively (nine studies with 6,968 cases and 9,126 controls for rs5275; three studies with 2,901 cases and 3,463 controls for rs20417; two studies with 5,551 cases and 6,208 controls for rs5277). No overall significant associations were observed in single-locus analysis between the three polymorphisms of COX-2 and breast cancer risk, though a borderline significant increased risk of breast cancer was detected with rs5277 in a recessive model (OR: 1.217, 95% CI: 0.958–1.547, P = 0.107). The results were not changed when studies were stratified by ethnicity. In conclusion, the present meta-analysis suggests that none of the most studied three SNPs (rs5275, rs20417, and rs5277) in the COX-2 gene is a conspicuous low-penetrant risk factor for developing breast cancer. There is a need for further large studies into the role of these polymorphisms (especially rs5277) and other potentially functional polymorphisms/haplotypes in the COX-2 gene as breast cancer risk modifiers.

[1]  M. Sanak,et al.  Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. , 2004, The Journal of allergy and clinical immunology.

[2]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[3]  D. Januszkiewicz-Lewandowska,et al.  Association of the heterozygous germline I171V mutation of the NBS1 gene with childhood acute lymphoblastic leukemia , 2006, Leukemia.

[4]  R. Cardiff,et al.  HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. , 2005, Cancer research.

[5]  A. Sahin,et al.  Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. , 2002, Cancer research.

[6]  S. Ethier,et al.  Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. , 2004, Molecular cancer research : MCR.

[7]  E. Seemanová,et al.  Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations , 2000, European Journal of Human Genetics.

[8]  K. Helzlsouer,et al.  Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease , 2006, Cancer.

[9]  Stephen B. Gruber,et al.  FGFR2 Is a Breast Cancer Susceptibility Gene in Jewish and Arab Israeli Populations , 2008, Cancer Epidemiology Biomarkers & Prevention.

[10]  B S Weir,et al.  Distributions of Hardy–Weinberg Equilibrium Test Statistics , 2008, Genetics.

[11]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[12]  Ariel Fernández,et al.  Protein Under-Wrapping Causes Dosage Sensitivity and Decreases Gene Duplicability , 2007, PLoS genetics.

[13]  D. Birnbaum,et al.  BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. , 1991, Oncogene.

[14]  J. Haines,et al.  Genome-wide association study identifies a novel breast cancer susceptibility locus at 6q25.1 , 2009, Nature Genetics.

[15]  M. Hung,et al.  Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. , 2004, Cancer cell.

[16]  Y. Aulchenko,et al.  Association of FGFR2 gene polymorphisms with the risk of breast cancer in population of West Siberia , 2009, European Journal of Human Genetics.

[17]  Ammarin Thakkinstian,et al.  A method for meta‐analysis of molecular association studies , 2005, Statistics in medicine.

[18]  S. Ethier,et al.  Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells , 2007, Journal of cellular physiology.

[19]  M. Rydzanicz,et al.  Increased risk of larynx cancer in heterozygous carriers of the I171V mutation of the NBS1 gene , 2007, Cancer Science.

[20]  V. P. Eswarakumar,et al.  Cellular signaling by fibroblast growth factor receptors. , 2005, Cytokine & growth factor reviews.

[21]  B. Paulweber,et al.  The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  Thea D. Tlsty,et al.  Benign breast disease and the risk of breast cancer. , 2005 .

[23]  J. G. Park,et al.  Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. , 2001, Cancer research.

[24]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[25]  L. Norton,et al.  Cyclooxygenase-2 Is Overexpressed in HER-2/neu-positive Breast Cancer , 2002, The Journal of Biological Chemistry.

[26]  N. Park,et al.  Polymorphism in the nuclear factor kappa-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. , 2005, Cancer letters.

[27]  R. Dumitrescu,et al.  Understanding breast cancer risk ‐ where do we stand in 2005? , 2005, Journal of cellular and molecular medicine.

[28]  W. Willett,et al.  A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer , 2007, Nature Genetics.

[29]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[30]  T. Dörk,et al.  NBS1 variant I171V and breast cancer risk , 2008, Breast Cancer Research and Treatment.

[31]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[32]  Peter Kraft,et al.  Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics , 2008, PLoS genetics.

[33]  John D Potter,et al.  Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. , 2008, JAMA.

[34]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[35]  R. Millikan,et al.  Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast , 2003, Cancer Causes & Control.

[36]  B. Ning,et al.  Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. , 2005, Gastroenterology.

[37]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[38]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[39]  D. Januszkiewicz-Lewandowska,et al.  I171V germline mutation in the NBS1 gene significantly increases risk of breast cancer , 2008, Breast Cancer Research and Treatment.

[40]  S. Humphries,et al.  Common Promoter Variant in Cyclooxygenase-2 Represses Gene Expression: Evidence of Role in Acute-Phase Inflammatory Response , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[41]  G. Jin,et al.  Functional Polymorphisms in the Cyclooxygenase 2 (COX-2) Gene and Risk of Breast Cancer in a Chinese Population , 2007, Journal of toxicology and environmental health. Part A.

[42]  M. Romano,et al.  Cyclooxygenase‐2 and 5‐lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  C. Dickson,et al.  Fibroblast growth factor signaling in tumorigenesis. , 2005, Cytokine & growth factor reviews.

[44]  K. Matsuo,et al.  FGFR2 intronic polymorphisms interact with reproductive risk factors of breast cancer: Results of a case control study in Japan , 2009, International journal of cancer.

[45]  Karl Sperling,et al.  Increased cancer risk of heterozygotes with NBS1 germline mutations in poland , 2004, International journal of cancer.

[46]  Y. Labrie,et al.  Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer , 2009, BMC Cancer.

[47]  T. Dörk,et al.  Nijmegen Breakage Syndrome mutations and risk of breast cancer , 2008, International journal of cancer.

[48]  Douglas F. Easton,et al.  Association studies for finding cancer-susceptibility genetic variants , 2004, Nature Reviews Cancer.

[49]  B. Ponder,et al.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[50]  R. Eeles,et al.  Genome-wide association studies in cancer. , 2008, Human molecular genetics.

[51]  A. Kluska,et al.  Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland , 2006, International journal of cancer.

[52]  R. Millikan,et al.  Cyclooxygenase 2 Polymorphism (Val511Ala), Nonsteroidal Anti-inflammatory Drug Use and Breast Cancer in African American Women , 2005, Cancer Epidemiology Biomarkers & Prevention.

[53]  R. Słomski,et al.  Heterozygous carriers of the I171V mutation of the NBS1 gene have a significantly increased risk of solid malignant tumours. , 2008, European journal of cancer.

[54]  Jin Li,et al.  STK15 F31I polymorphism is associated with breast cancer risk: a meta-analysis involving 25,014 subjects , 2009, Breast Cancer Research and Treatment.

[55]  Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk , 2006, Breast Cancer Research.

[56]  A. Jakubowska,et al.  Breast cancer predisposing alleles in Poland , 2005, Breast Cancer Research and Treatment.

[57]  U. Vogel,et al.  Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. , 2006, Carcinogenesis.

[58]  J. Baron,et al.  Nonsteroidal anti-inflammatory drugs and cancer prevention. , 2000, Annual review of medicine.

[59]  N. Miller,et al.  Low penetrance breast cancer predisposition SNPs are site specific , 2009, Breast Cancer Research and Treatment.

[60]  Maria Chosia,et al.  Germline 657del5 mutation in the NBS1 gene in breast cancer patients , 2003, International journal of cancer.

[61]  J. Limon,et al.  Germline NBS1 mutations in families with aggregation of Breast and/or ovarian cancer from north-east Poland. , 2007, Anticancer research.

[62]  J. Buring,et al.  A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study , 2007, Breast Cancer Research.

[63]  L. Fan,et al.  A functional polymorphism in the promoter region of GSTM1 implies a complex role for GSTM1 in breast cancer , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  R. Wilkins.  Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[65]  J. Chang-Claude,et al.  Determination of the frequency of the common 657Del5 Nnijmegen breakage syndrome mutation in the German population: No association with risk of breast cancer , 1999, Genes, chromosomes & cancer.

[66]  P. Devilee,et al.  NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia , 2005, International journal of cancer.

[67]  D. Easton,et al.  Common Polymorphisms in the Prostaglandin Pathway Genes and Their Association with Breast Cancer Susceptibility and Survival , 2009, Clinical Cancer Research.

[68]  X. Wang,et al.  A novel single nucleotide polymorphism of the cyclooxygenase-2 gene associated with breast cancer. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

[69]  Wei Zhu,et al.  −765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: a meta-analysis based on 33 case–control studies , 2009, Molecular Biology Reports.